|
|
Blood, 1 April 2004, Vol. 103, No. 7, pp. 2571-2576.
Prepublished online as a Blood First Edition Paper on November 13, 2003; DOI 10.1182/blood-2003-07-2316.

Submitted July 11, 2003
Accepted October 28, 2003
Severe hypodysfibrinogenemia in compound heterozygotes of the fibrinogen A IVS4+1 G>T mutation and an A Gln328 truncation (Fibrinogen Keokuk)
Phil Lefebvre, Pauline T Velasco, Amy Dear, Karim C Lounes, Susan T Lord, Stephan O Brennan, David Green*, and Laszlo Lorand
Department of Cell and Molecular Biology, Northwestern University, Chicago, IL, USA
Department of Medicine, Northwestern University, Chicago, IL, USA
Molecular Pathology Laboratory, Canterbury Health Laboratories, Christchurch, New Zealand
Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC, USA
* Corresponding author; email: d-green{at}northwestern.edu.
Two hypofibrinogenemic siblings have lifelong trauma-related bleeding. Recently, the brother suffered recurrent thrombosis after cryoprecipitate infusions post-surgery; the sister has suffered six miscarriages. Their plasma clots were resistant to compression and fibrinolysis, and soluble in 5M urea. Examination by SDS-PAGE revealed only the presence of crosslinked - fibrin chain dimers without high polymers of n. Fibrin clots contained an abnormal 35 kDa constituent recognized by an antibody to fibrinogen A chain residues 241-476 but not by antibodies to A 291-348 or A 349-406. DNA analysis revealed a heterozygous CAA TAA mutation at codon 328 of the A gene in these siblings and 2 asymptomatic family members. The Gln328stop mutation (Fibrinogen Keokuk) predicted a 46% truncation and the production of a 35 kDa A chain. Analysis of purified fibrinogen revealed expression of the abnormal A chain in the 4 family members, but found no normal fibrinogen in the 2 hypofibrinogenemic patients. This paradox was resolved when they, and their asymptomatic mother, were found to be heterozygous for a second A mutation, a GT TT splice site mutation in intron 4 (IVS4+1 G>T). However, compound heterozygosity for both mutations was required for the expression of severe hypodysfibrinogenemia and clinical symptoms.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. Uitte de Willige, K. F. Standeven, H. Philippou, and R. A. S. Ariens
The pleiotropic role of the fibrinogen {gamma}' chain in hemostasis
Blood,
November 5, 2009;
114(19):
3994 - 4001.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. O. Brennan, R. L. Davis, R. Lowen, and A. Ruskova
Deletion of five residues from the coiled coil of fibrinogen (B{beta} Asn167_Glu171del) associated with bleeding and hypodysfibrinogenemia
Haematologica,
April 1, 2009;
94(4):
585 - 588.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Lorand
Crosslinks in blood: transglutaminase and beyond
FASEB J,
June 1, 2007;
21(8):
1627 - 1632.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Park, H.-J. Doh, S.-S. A. An, J.-R. Choi, K.-H. Chung, and K.-S. Song
A novel fibrinogen variant (fibrinogen Seoul II; A{alpha}Gln328Pro) characterized by impaired fibrin {alpha}-chain cross-linking
Blood,
September 15, 2006;
108(6):
1919 - 1924.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. S. Song, N. J. Park, J. R. Choi, H. J. Doh, and K. H. Chung
Fibrinogen Seoul (FGG Ala341Asp): A Novel Mutation Associated With Hypodysfibrinogenemia
Clinical and Applied Thrombosis/Hemostasis,
July 1, 2006;
12(3):
338 - 343.
[Abstract]
[PDF]
|
 |
|
|
|